By: IPP Bureau
Last updated : August 27, 2026 7:27 pm
The company’s Sustainability Report 2025–26 highlights progress across ESG priorities
Piramal Pharma Limited has released its Sustainability Report 2025–26, outlining progress across environmental, social and governance (ESG) priorities and highlighting the integration of sustainability into the company’s business strategy, operations and innovation agenda.
The report, themed “Advancing Innovation, Leveraging Sustainability,” highlights the company’s efforts to reduce its environmental footprint, strengthen operational and quality standards, enhance employee development and expand its social impact.
Piramal Pharma reported a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with its FY2022 baseline, while renewable energy accounted for 41% of total energy consumption across its operations.
The company also recycled and reused 2.63 lakh kilolitres of freshwater and diverted 65% of its total waste for recycling.
The company said it continued to advance its decarbonisation roadmap aligned with its Science Based Targets initiative (SBTi)-approved targets, alongside initiatives focused on resource efficiency and responsible operations.
Piramal Pharma successfully completed 38 regulatory inspections, including three USFDA inspections with zero Official Action Indicated (OAI) observations. It also completed 209 customer audits across its global manufacturing network.
On governance and people, Piramal Pharma reported zero data breach incidents and zero corruption cases during the reporting period. ESG training was completed by 100% of employees, while the entire workforce completed Code of Conduct training. Women accounted for 30% of the Board and 20.1% of the global workforce.
The company also expanded its responsible supply-chain programme, with 38% of critical suppliers assessed against sustainability criteria during the year.
Piramal Pharma invested Rs. 8.98 crore in CSR initiatives during FY2025–26, with its healthcare and education programmes reaching nearly 1.8 million people across 112 Aspirational Districts.
Nandini Piramal, Chairperson, Piramal Pharma Limited, said sustainability is being viewed by the company as a catalyst for innovation, resilience and long-term growth rather than simply a responsibility.
“The progress reflected in this year’s Sustainability Report gives us confidence in the direction we are taking. We believe that innovation and sustainability can reinforce one another, enabling us to make better decisions today while creating greater value for tomorrow,” Piramal said.